History of poliomyelitis Hospital, successfully cultivated the poliovirus in human tissue. This significant breakthrough ultimately allowed for the development of the polio vaccines. Enders and his colleagues, Thomas H. Weller and Frederick C. Robbins, were recognized for their labors with the Nobel Prize in 1954. Two vaccines are used throughout the world to combat polio. The first was developed by Jonas Salk, first tested in 1952, and announced to the world by Salk on April 12, 1955. The Salk vaccine, or "inactivated poliovirus vaccine" (IPV), consists of an injected dose of killed poliovirus. In 1954, the vaccine was tested for its ability to
SAV001 a feasible option for an HIV vaccine. Indeed, Jonas Salk developed a therapeutic HIV vaccine in 1987, called Remune now being developed by Immune Response BioPharma, Inc., is based on the killed whole virus approach. Remune vaccine has completed over 25 clinical studies to date and showed a robust mechanism of action restoring white blood cell counts in CD4 & CD8 T cells by reducing viral load and increasing immunity. Also, a group of researchers and professionals in the field of HIV strongly advocates that the killed HIV approach must be taken to fight back the global HIV and AIDS